title: Analysis of 2'5' oligo (A) synthetase in patients with advanced thyroid carcinoma.
authors.forename: I
authors.initials: I
authors.lastname: Vainas
authors.forename: K
authors.initials: K
authors.lastname: Dimitriadis
authors.forename: I
authors.initials: I
authors.lastname: Stergiou
authors.forename: I
authors.initials: I
authors.lastname: Tsirintanis
authors.forename: G
authors.initials: G
authors.lastname: Galaktidou
authors.forename: A H
authors.initials: AH
authors.lastname: Kortsaris
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology* / Q000628:therapy; D003131:Combined Modality Therapy; D004790:Enzyme Induction / Q000187:drug effects; D015251:Epirubicin / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D016898:Interferon-alpha / Q000494:pharmacology* / Q000627:therapeutic use; D011446:Prospective Studies; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000628:therapy
chemical_list: D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D007155:Immunologic Factors; D016898:Interferon-alpha; D015251:Epirubicin; D005047:Etoposide; D016190:Carboplatin; D015088:2',5'-Oligoadenylate Synthetase; D007069:Ifosfamide